The place occupied by France in the world organization of clinical trials of medications is apparently stable. The investigation made public Friday, 21 November, The Business of the drug (LEEM), the fourth of its kind, was conducted among 19 pharmaceutical companies (including eight found in the top ten global). It shows that in 2008 France was - as in 2006 -, 8% of patients recruited, or more than 24 000 patients for almost 400 clinical studies.
A 9 hours by e-mail, receive the titles of the newspaper to be published in the afternoon.
Subscribe to Monde.fr: € 6 per month + 30 days offered
On the same subject
The Medical Research made a concentrated effort in North
Viewpoint Cancer: the words to say, by Jacqueline Hénard
Compared to the 2006 survey, this stability is in fact an erosion relative to the East who earn "market share" from 15% in 2006 to 18% in 2008. The weight of the United States is reduced by 17% in 2006 to 13% in 2008.
More than half of studies conducted by international laboratories are not proposed to France (30% in 2006), but France says, however, a growing specialization in oncology, hematology and infectious diseases (vaccines). These three therapeutic areas totaled 77% of the total number of patients recruited in France, 20 321 people.
Clinical trials are a key funding for hospitals and doctors are an essential tool to upgrade their knowledge. For emerging countries, they are a tool for modernizing the hospital and a means to provide patients the most innovative molecules sick they have no access.
A 9 hours by e-mail, receive the titles of the newspaper to be published in the afternoon.
Subscribe to Monde.fr: € 6 per month + 30 days offered
On the same subject
The Medical Research made a concentrated effort in North
Viewpoint Cancer: the words to say, by Jacqueline Hénard
Compared to the 2006 survey, this stability is in fact an erosion relative to the East who earn "market share" from 15% in 2006 to 18% in 2008. The weight of the United States is reduced by 17% in 2006 to 13% in 2008.
More than half of studies conducted by international laboratories are not proposed to France (30% in 2006), but France says, however, a growing specialization in oncology, hematology and infectious diseases (vaccines). These three therapeutic areas totaled 77% of the total number of patients recruited in France, 20 321 people.
Clinical trials are a key funding for hospitals and doctors are an essential tool to upgrade their knowledge. For emerging countries, they are a tool for modernizing the hospital and a means to provide patients the most innovative molecules sick they have no access.
No comments:
Post a Comment